Literature DB >> 8818655

19p+ marker chromosome correlates with relapse in malignant fibrous histiocytoma.

P F Choong1, N Mandahl, F Mertens, H Willén, T Alvegård, A Kreicbergs, F Mitelman, A Rydholm.   

Abstract

In this study, we examined the relationship of 19p13 aberrations, usually leading to addition of unknown material (19p+), and ring chromosomes to clinical outcome in patients with malignant fibrous histiocytoma (MFH). Analysis of 69 MFHs revealed 19 tumors with 19p+ and 24 tumors with ring chromosomes. After a median follow-up period of 36 months, 24 patients developed metastases, and 27 patients developed local recurrences. Ten patients had both local recurrences and metastases. Local recurrence was more common in association with 19p+ than without. Metastasis was more common with 19p+ tumors in high-risk patients (tumor size > 5 cm and grade III-IV; n = 48) than those without 19p+. There was a trend suggesting fewer relapses after tumors with ring chromosomes. 19p+ may be an independent marker of unfavorable outcome in MFH.

Entities:  

Mesh:

Year:  1996        PMID: 8818655     DOI: 10.1002/(SICI)1098-2264(199606)16:2<88::AID-GCC2>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker.

Authors:  M L Larramendy; M Tarkkanen; C Blomqvist; M Virolainen; T Wiklund; S Asko-Seljavaara; I Elomaa; S Knuutila
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Proposal for Modification of Cahan's Criteria Utilizing Molecular Genetic Analyses for Cases without Baseline Histopathology: A Unique Method Applicable to Primary Radiosurgery.

Authors:  Aaron E Rusheen; James B Smadbeck; Lisa A Schimmenti; Eric W Klee; Michael J Link; George Vasmatzis; Matthew L Carlson
Journal:  J Neurol Surg B Skull Base       Date:  2018-05-31

3.  Establishment of a new human pleomorphic malignant fibrous histiocytoma cell line, FU-MFH-2: molecular cytogenetic characterization by multicolor fluorescence in situ hybridization and comparative genomic hybridization.

Authors:  Jun Nishio; Hiroshi Iwasaki; Kazuki Nabeshima; Masako Ishiguro; Teruto Isayama; Masatoshi Naito
Journal:  J Exp Clin Cancer Res       Date:  2010-11-24

4.  Characterization of the new human pleomorphic undifferentiated sarcoma TP53-null cell line mfh-val2.

Authors:  Rosario Gil-Benso; Javier Megías; Teresa San-Miguel; Sandra Pinto; Robert C Callaghan; Concha López-Ginés; Miguel Cerdá-Nicolás
Journal:  Cytotechnology       Date:  2017-07-04       Impact factor: 2.058

5.  Gain of 17q in malignant fibrous histiocytoma is associated with a longer disease-free survival and a low risk of developing distant metastasis.

Authors:  W-H Weng; J Ahlén; W-O Lui; O Brosjö; S-T Pang; A Von Rosen; G Auer; O Larsson; C Larsson
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

6.  Myxoid malignant fibrous histiocytoma with multiple primary sites.

Authors:  Jeffrey H Muler; Augusto F Paulino; Diane Roulston; Laurence H Baker
Journal:  Sarcoma       Date:  2002

7.  Sarcomas of the heart as a difficult interdisciplinary problem.

Authors:  Stanisław Ostrowski; Anna Marcinkiewicz; Anna Kośmider; Ryszard Jaszewski
Journal:  Arch Med Sci       Date:  2014-02-23       Impact factor: 3.318

8.  Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line.

Authors:  Giacomo Miserocchi; Alessandro De Vita; Laura Mercatali; Federica Recine; Chiara Liverani; Chiara Spadazzi; Federica Pieri; Nada Riva; Alberto Bongiovanni; Roberto Casadei; Valentina Fausti; Toni Ibrahim
Journal:  Cells       Date:  2018-10-25       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.